{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"5","value":"4"},{"groupId":"OG001","lowerLimit":"7","upperLimit":"16","value":"11"},{"groupId":"OG002","lowerLimit":"2","upperLimit":"19","value":"11"},{"groupId":"OG003","lowerLimit":"8","upperLimit":"35","value":"22"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"366"},{"groupId":"OG001","value":"156"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"29"}],"units":"Participants"}],"description":"TRM is defined as death occurring in a patient from causes other than relapse or progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Tandem autologous transplant plus thalidomide/dexamethasone or observation for standard risk patients","id":"OG000","title":"Auto-Auto Standard Risk"},{"description":"Autologous transplant plus non-myeloablative allogeneic transplant for standard risk patients","id":"OG001","title":"Auto-Allo Standard Risk"},{"description":"Tandem autologous transplant plus thalidomide/dexamethasone or observation for high risk patients","id":"OG002","title":"Auto-Auto High Risk"},{"description":"Autologous transplant plus non-myeloablative allogeneic transplant for high risk patients","id":"OG003","title":"Auto-Allo High Risk"}],"paramType":"NUMBER","populationDescription":"Patients that completed second transplant","reportingStatus":"POSTED","timeFrame":"Year 3","title":"Cumulative Incidence of Treatment Related Mortality (TRM)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}